P/E ratio for Hikma Pharmaceuticals (HIK.L)
P/E ratio at the end of 2022: 23.5
According to Hikma Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2022 the company had a P/E ratio of 23.5.
P/E ratio history for Hikma Pharmaceuticals from 2005 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 23.5 | 51.9% |
| 2021 | 15.5 | -12.32% |
| 2020 | 17.6 | 38.54% |
| 2019 | 12.7 | -31.21% |
| 2018 | 18.5 | -551.44% |
| 2017 | -4.10 | -111.34% |
| 2016 | 36.1 | 57.23% |
| 2015 | 23.0 | 29.62% |
| 2014 | 17.7 | 25.34% |
| 2013 | 14.1 | -26.05% |
| 2012 | 19.1 | 0.38% |
| 2011 | 19.1 | -4.91% |
| 2010 | 20.0 | 25.14% |
| 2009 | 16.0 | 10.13% |
| 2008 | 14.5 | -12.7% |
| 2007 | 16.7 | 17.12% |
| 2006 | 14.2 | -16.96% |
| 2005 | 17.1 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.